1. Home
  2. MATV vs ARVN Comparison

MATV vs ARVN Comparison

Compare MATV & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mativ Holdings Inc.

MATV

Mativ Holdings Inc.

N/A

Current Price

$11.75

Market Cap

665.6M

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$6.84

Market Cap

600.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MATV
ARVN
Founded
1995
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
665.6M
600.2M
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
MATV
ARVN
Price
$11.75
$6.84
Analyst Decision
Buy
Analyst Count
0
15
Target Price
N/A
★ $14.00
AVG Volume (30 Days)
457.4K
★ 859.5K
Earning Date
11-04-2026
11-03-2026
Dividend Yield
★ 3.33%
N/A
EPS Growth
N/A
★ 58.84
EPS
N/A
★ 0.88
Revenue
N/A
★ $262,600,000.00
Revenue This Year
$0.71
$5.67
Revenue Next Year
$3.32
N/A
P/E Ratio
★ N/A
$7.78
Revenue Growth
★ N/A
N/A
52 Week Low
$7.07
$6.33
52 Week High
$15.48
$14.22

Technical Indicators

Market Signals
Indicator
MATV
ARVN
Relative Strength Index (RSI) 49.21 41.87
Support Level $11.43 $6.74
Resistance Level $12.59 $7.85
Average True Range (ATR) 0.59 0.47
MACD 0.04 -0.03
Stochastic Oscillator 41.74 27.06

Price Performance

Historical Comparison
MATV
ARVN

About MATV Mativ Holdings Inc.

Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: